Notícias e Atividades da Scilex Pharmaceuticals

A Scilex Pharmaceuticals pertence à Sorrento Therapeutics.

Sorrento Therapeutics é uma empresa listada sob o símbolo SRNE (US).

Veja o organograma con seus 12 executivos principais

Biografias mais buscadas da Scilex Pharmaceuticals

• Jay Chun, Director
• Dorman Followwill, Director
• Henry Ji, Chairman of the Board

Criar um alerta
para seguir os movimentos de executivos da Scilex Pharmaceuticals.

Sorrento Therapeutics possui 1.913 concorrentes concorrentes Sanofi (França), Eli Lilly (Estados Unidos) e Moderna (Estados Unidos).

Popular M&A news in Farmacêutica

• Contraline acaba de anunciar uma arrecadação de fundos de 93 milhões de dólares. (publicado em 3 de junho de 2026).
• Hims & Hers adquiriu Eucalyptus (publicado em 2 de junho de 2026).
• Apotex preencheu seu dossiê de IPO. Seu símbolo de ação será TSX. (publicado em 2 de junho de 2026).

Outros contatos sugeridos na indústria do Farmacêutica

• Joaquin Duato - Chief Executive Officer and Chairman of the Board da Johnson & Johnson
• Richard Saynor - Chief Executive Officer da Sandoz
• Robert Ford - Chief Executive Officer and Chairman of the Board da Abbott

Saiba mais sobre a indústria do Farmacêutica

Últimos comunicados de imprensa de Scilex Pharmaceuticals

• News & Events – Scilex Holding
• News & Events - Scilex Holding
• News - Scilex Holding
• Scilex Announces Addition of ZTlido® to Express Scripts National Formularies - Scilex Holding
• Scilex Holding Company, a Sorrento Therapeutics, Inc. Subsidiary Announces Expansion of Ztlido® Managed Care Coverage for Additional 33 Million Lives – SCILEX Pharmaceutical
• Scilex Holding Company, a Sorrento Company, Announces Complete Enrollment on Non-Opioid Injectable SP-102 (SEMDEXA™) Phase 3 Pivotal Trial C.L.E.A.R. Program For Sciatica Pain Management – SCILEX Pharmaceutical
• Scilex Holding, A Subsidiary of Sorrento, Has Received From FDA a sNDA Approval for Ztlido® Label Expansion – SCILEX Pharmaceutical
• Sorrento Therapeutics and Scilex Holding, a Majority Owned Subsidiary, Have Entered Into an Exclusive Licensing Term Sheet With Aardvark Therapeutics to Acquire Its ARD-301 For the Treatment of Chronic Pain, Fibromyalgia, and Chronic Long Haul Covid Syndr
• Scilex Holding Company, a Subsidiary of Sorrento Therapeutics, Announces Continuous Sales Growth in ZTlido® and Expects to Complete Enrollment on its SP-102 (SEMDEXA™) Phase 3 Pivotal Trial Program in 2020 – SCILEX Pharmaceutical
• Sorrento COVID-19 R&D October 13, 2020 Pipeline Call Details Released – SCILEX Pharmaceutical
• View more press releases Close

Redes sociais sobre Scilex Pharmaceuticals

• Scilex Pharmaceuticals na Wikipedia, Google News e Yahoo Finance
• Scilex Pharmaceuticals na LinkedIn, X (Twitter) e YouTube